Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
about
Genome-editing Technologies for Gene and Cell TherapyEnabling functional genomics with genome engineeringSynthetic biology approaches to engineer T cellsChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetA new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19Progress and prospects for engineered T cell therapiesToward beta cell replacement for diabetesSmart CARs engineered for cancer immunotherapyBanking on iPSC--is it doable and is it worthwhileGenome-Edited T Cell Therapies.Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.Engineered T cells for cancer therapy.Cytokine-induced killer (CIK) cells: from basic research to clinical translation.Challenges and opportunities of allogeneic donor-derived CAR T cellsNew Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target MalignanciesGenetic editing of HLA expression in hematopoietic stem cells to broaden their human application.A genome editing primer for the hematologistCD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Reprogramming MHC specificity by CRISPR-Cas9-assisted cassette exchange.Adoptive immunotherapy for cancer or viruses.Clinical utility of natural killer cells in cancer therapy and transplantation.Stem cell-based therapies for cancer treatment: separating hope from hype.Towards a commercial process for the manufacture of genetically modified T cells for therapy.Adoptive cellular therapy: a race to the finish line.Avoiding immunological rejection in regenerative medicine.Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery.Current status of chimeric antigen receptor therapy for haematological malignancies.The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.Engineered T cells: the promise and challenges of cancer immunotherapy.Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.The present and future of genome editing in cancer research.Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.Concise Review: One Stone for Multiple Birds: Generating Universally Compatible Human Embryonic Stem Cells.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Selective immunotargeting of diabetogenic CD4 T cells by genetically redirected T cells.Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.Cornerstones of CRISPR-Cas in drug discovery and therapy.Delivery technologies for genome editing.
P2860
Q26769662-C87C13B4-5D71-43C5-861A-0590A1683B6CQ26782747-545B2F60-257B-4848-B93D-D4BA133DB1F2Q26798366-40B1F508-3E9D-44DB-98A1-DE12DB76F23BQ26799357-D75D7D8A-84D4-4745-81C8-9F356BBC2838Q26849476-B6B0117A-23A3-4F39-8F8C-DAC36A743B9FQ26852923-99E584AD-0968-4AA2-ABF3-C53AD8AE0CEEQ28083650-554429A5-02D5-4570-97AF-1263FF20D45EQ28087236-F7C10421-C1CD-4884-A1CB-C02194D353B2Q28254023-345AEDC2-A45F-4634-A788-E155E22D79B5Q33729598-6D38BABE-FE68-4525-B465-A32E14B12162Q34047618-B044571D-E551-4EEC-BF92-E047F7379D6FQ34080368-8693DB54-9028-441D-897B-E3C7B5D31A09Q36121153-6150BF69-D728-4D9C-AC6E-0057CFD1F959Q36257036-3F6B6F19-3D07-459B-BD6D-589CCAE742E8Q36558375-811B5FBC-FE1B-43D1-990F-0C7475B25DC3Q36605814-7A8914D4-9D99-4D91-9C0D-B210601D1FECQ36942027-4B9ED1E8-12AF-42CF-A586-D27A62D275D0Q36951719-DFEE41C2-D667-4109-A2F6-481C2625C7F2Q37723469-D563584E-E194-4A9E-8CBC-7A6B29E98FA3Q37736679-5DEDA133-4E48-4530-97C4-64EF5C740BA3Q38178359-91F16F00-F7F6-48DE-8F9D-294E158FABFAQ38195120-E28B97A1-902A-4398-A899-2A786EB7CB60Q38245163-3F7C3B33-8787-44F6-A52B-BC3CA8C1A271Q38329158-A84EC761-371E-4B11-A087-402525613E1DQ38391528-5A8309CA-4FC2-4FFE-A3E9-872CD8E0C7D9Q38453650-37DD6B7E-4347-4166-896C-776837805874Q38530599-011E2E23-4CFB-4425-B347-95D08DC06F7FQ38631108-4CF3B4A0-621D-46DD-B078-ED90285DC649Q38670431-EDB013E2-81BF-4D1B-9206-A2251274F0ECQ38828829-5419544B-E03B-421E-97BE-F20D2AEA6A2AQ38839878-F0A88F2A-68D2-42AB-A271-91A818D33CFCQ38840267-129055AB-48E3-413C-AD0E-DFFB20A9C74BQ38849182-7E95C088-5CED-463E-9EE7-212B260646C6Q38850651-E46D0467-1237-47EE-AF22-57F4E8BDFB82Q38913549-0809B3A9-0FD6-401F-BB0D-7F4CE32D16EAQ38983184-09D8B224-049B-42FB-B0C2-42A040B5E851Q39037477-2AD0DE2F-2945-447D-B10E-C2808D3E932BQ39045586-CE82F59B-4109-4A36-B2FB-5E494E9A66EEQ39051110-933DD2FF-7201-4A9F-BB3C-BFA083297196Q39197557-95F0F738-38D0-4FAC-8441-4301106F05B7
P2860
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Toward eliminating HLA class I ...... l cells from allogeneic donors
@en
Toward eliminating HLA class I ...... cells from allogeneic donors.
@nl
type
label
Toward eliminating HLA class I ...... l cells from allogeneic donors
@en
Toward eliminating HLA class I ...... cells from allogeneic donors.
@nl
prefLabel
Toward eliminating HLA class I ...... l cells from allogeneic donors
@en
Toward eliminating HLA class I ...... cells from allogeneic donors.
@nl
P2093
P2860
P50
P1433
P1476
Toward eliminating HLA class I ...... l cells from allogeneic donors
@en
P2093
Andreas Reik
Carrie Yuen
Denise L Crossland
Edward J Rebar
Frank Soldner
Helen Huls
Hiroki Torikai
Jeffrey C Miller
Laurence J N Cooper
Michael C Holmes
P2860
P304
P356
10.1182/BLOOD-2013-03-478255
P407
P577
2013-06-05T00:00:00Z